In
what has become a red-hot stock market for med-tech stocks, it's the
rare quality company that hasn't taken part in the rally. As a huge
player in drugs, devices, and OTC consumer healthcare products,
Johnson & Johnson
(NYSE: JNJ) has certainly been carried along by this healthcare
lovefest – the shares are up nearly 40% over the past year, and
only a small handful of other large companies (Stryker
(NYSE: SYK) and Roche
(Nasdaq: RHHBY), for instance) can come close to matching or
exceeding Johnson & Johnson.
The
curious thing about this performance is that it hasn't accompanied
strong, even financial performance. JNJ's drug business has roared
back to life, but the device business continues to struggle with a
difficult environment and past mistakes, while the consumer business
tries to recover from the reputation and market share damage incurred
by the spate of recalls and contamination problems a few years ago.
Please read more here:
http://www.massdevice.com/blogs/massdevice/can-johnson-johnson-fire-all-cylinders-again
No comments:
Post a Comment